Market Overview

UPDATE: Morgan Stanley Initiates Neurocrine Biosciences at Overweight on Asset Quality

Related NBIX
Benzinga's Top Initiations
25 Stocks Which Rallied Four Days, Then Sold Off Yesterday

Morgan Stanley initiated its coverage on Neurocrine Biosciences (NASDAQ: NBIX) with an Overweight rating and a $12 price target.

Morgan Stanley said, "Neurocrine has a differentiated lead asset, elagolix, targeting large markets with segments of unmet need. We believe the Street undervalues this asset. We expect elagolix success in endometriosis and uterine fibroids (UF) and model combined WW sales of ~$720mn in 2020."

Neurocrine Biosciences closed at $8.30 on Wednesday.

Latest Ratings for NBIX

Oct 2016NeedhamInitiates Coverage OnBuy
Oct 2016Leerink SwannAssumesOutperform
Jun 2016H.C. WainwrightInitiates Coverage onBuy

View More Analyst Ratings for NBIX
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (NBIX)

View Comments and Join the Discussion!